Targeted Genetics gains on Mydicar data

Targeted Genetics Corp. (Pink:TGEN) gained $0.08 (35%) to $0.31 on Wednesday after partner Celladon Corp. (La Jolla, Calif.) said Mydicar met the primary efficacy endpoint in the Phase II portion of the Phase I/II CUPID trial to treat class III/IV heart failure. Mydicar met the endpoint of a significant reduction vs. placebo in a composite of outcome measures, including worsening of heart failure leading to hospitalization, frequency of and time to cardiac transplantation or left ventricular assist device implantation, changes in the patients' ability to exercise, echocardiographic assessments, symptoms of heart failure and a blood test for the heart failure biomarker NT-proBNP. Celladon also said that Mydicar met the study's primary safety endpoint. ...